A 12-Week Open-Label Followed by 4-Week Double-Blind Study to Determine the Safety and Efficacy of an Extended Course of Alefacept (LFA-3/IgG1 Fusion Protein) in Subjects With Chronic Plaque Psoriasis.
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Alefacept (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 29 Nov 2008 New trial record.